PHARMACOGENETIC MARKERS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY - PubMed
5 days ago
- #pediatric oncology
- #personalized medicine
- #pharmacogenetics
- Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
- Treatment protocols for ALL involve combinations of chemotherapeutic drugs, which complicate toxicity assessment.
- Variability in toxic responses to ALL therapy may be influenced by gene variants affecting drug pharmacokinetics and pharmacodynamics.
- The review analyzes pharmacogenetic markers for drugs like anthracyclines, vincristine, glucocorticoids, L-asparaginase, methotrexate, alkylating agents, 6-mercaptopurine, cytarabine, and etoposide.
- Only TPMT and NUDT15 genes currently have well-established clinical utility in ALL therapy.
- The clinical relevance of other pharmacogenetic markers in pediatric ALL remains under investigation.
- The review identifies knowledge gaps and suggests future research directions for integrating pharmacogenetic testing into personalized ALL treatment.